What is the torsemide (generic) equivalent dose to furosemide (Lasix) 240 mg?

Torsemide Equivalent Dose to Furosemide 240 mg

The torsemide equivalent to furosemide 240 mg is approximately 60 mg orally once daily, based on a 4:1 dose conversion ratio.

Dose Conversion Ratios

The most recent and highest-quality evidence from the TRANSFORM-Mechanism trial 1 demonstrates that a 4:1 dose equivalence (furosemide:torsemide) results in similar natriuresis. This contradicts the traditional 2:1 ratio that has been commonly used in clinical practice.

Key Evidence Supporting 4:1 Ratio:

• The 2025 TRANSFORM-Mechanism trial found that when clinicians used the traditional 2:1 conversion, torsemide produced substantially greater natriuresis than furosemide (P < 0.001) 1
• This excessive diuresis with the 2:1 ratio led to greater neurohormonal activation, kidney dysfunction, and perturbations in renal function without improving plasma volume or body weight 1
• A 4:1 dose equivalence resulted in comparable natriuresis between the two agents 1

Traditional Guideline Recommendations:

While older guidelines and FDA labeling suggest different ratios, they lack the mechanistic precision of recent trials:

• FDA labeling lists maximum doses of 600 mg/day for furosemide and 200 mg/day for torsemide (approximately 3:1 ratio) 2
• 2019 ACC Expert Consensus shows usual outpatient dosing of 20-80 mg furosemide vs 10-40 mg torsemide (2:1 to 4:1 range) 3
• 2013 ACCF/AHA Guidelines list maximum doses suggesting a 3:1 ratio 4

Practical Application for Furosemide 240 mg:

Given furosemide 240 mg daily:

• Using 4:1 ratio: 240 ÷ 4 = 60 mg torsemide once daily
• Using traditional 2:1 ratio: 240 ÷ 2 = 120 mg torsemide (likely excessive)

Important Caveats:

Bioavailability differences matter: Torsemide has superior and more consistent oral bioavailability (80-90%) compared to furosemide (10-90%, average ~50%) 5. However, the TRANSFORM-Mechanism trial found that kidney bioavailability (the proportion delivered to the tubular site of action) was actually lower with torsemide (17.1% vs 24.8%, P < 0.001) 1.

Duration of action: While torsemide has a longer half-life (12-16 hours vs 6-8 hours for furosemide) 4, 6, the TRANSFORM-Mechanism trial showed furosemide had longer duration of kidney drug delivery and natriuresis 1.

Monitoring and Titration:

When converting from furosemide 240 mg to torsemide:

1. Start with 60 mg torsemide once daily (4:1 conversion)
2. Monitor closely within 3-7 days: Check weight, symptoms, blood pressure, serum creatinine, and electrolytes (particularly potassium)
3. Titrate based on response: If inadequate diuresis, increase by doubling the dose; if excessive diuresis or renal dysfunction develops, reduce dose
4. Watch for safety signals: The 2025 comparative effectiveness study found torsemide associated with slightly increased acute kidney injury risk (HR 1.12) compared to furosemide 7

Clinical Context:

The 2025 TRANSFORM-Mechanism trial definitively showed no meaningful pharmacokinetic or pharmacodynamic advantages for torsemide over furosemide 1. The main TRANSFORM trial found no difference in all-cause mortality between the two agents 8. Therefore, the choice between agents should be based on individual patient factors, cost, and tolerability rather than assumptions of superiority.

For a patient on furosemide 240 mg daily (a high dose suggesting refractory edema), consider whether:

• Dietary sodium restriction is adequate
• NSAIDs or other interfering medications are present
• Renal function is significantly impaired
• Sequential nephron blockade (adding thiazide-type diuretic) might be more appropriate than simply switching loop diuretics 3, 4